Hudson Bay Capital Management
RPRX

Hudson Bay Capital Management’s Repros Therapeutics Inc. RPRX Stock Holding History

Hudson Bay Capital Management’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-95,471
Closed -$44K – 630
2017
Q2 		$44K Buy
+95,471
New +$69.3K ﹤0.01% 497

Other funds holding RPRX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AIA
Allegis Investment Advisors Idaho Falls, Idaho $326M AUM 10.36% 1-Year Est. Return
GAI
General American Investors New York $1.69B AUM 40.94% 1-Year Est. Return
VF
Virtu Financial New York $3.18B AUM 65.92% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
California Public Employees Retirement System
California Public Employees Retirement System Sacramento, California $177B AUM 39.86% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Hudson Bay Capital Management's RPRX Position: Q3 2017 in Review

Hudson Bay Capital Management sold out of Repros Therapeutics Inc. (RPRX) in Q3 2017, closing a stake of 95,471 shares — an estimated $44K sold.

Hudson Bay Capital Management first reported a position in RPRX in Q2 2017 and held it in 1 quarter. The position peaked at $44K in Q2 2017. 28 funds tracked by Wall St. Rank hold RPRX as of Q3 2017.

  • Hudson Bay Capital Management reported no remaining Repros Therapeutics Inc. position as of Q3 2017 after selling out during the quarter.
  • Hudson Bay Capital Management sold 95,471 Repros Therapeutics Inc. shares in Q3 2017, an estimated $44K.
  • Hudson Bay Capital Management first reported a position in Repros Therapeutics Inc. in Q2 2017 and held it in 1 quarter.
  • Hudson Bay Capital Management's Repros Therapeutics Inc. position peaked at $44K in Q2 2017.
  • 28 funds tracked by Wall St. Rank held Repros Therapeutics Inc. as of Q3 2017.

Based on Hudson Bay Capital Management's 13F filing for Q3 2017, filed 13 Nov 2017.